Integrating Phase 2 Into Phase 3 Based on an Intermediate Endpoint While Accounting for a Cure Proportion—With an Application to the Design of a Clinical Trial in Acute Myeloid Leukemia

Pharmaceutical Statistics - United Kingdom
doi 10.1002/pst.1969
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley


Related search